FindMyKOL

Richard Zuniga, MD

Enriched profile

Chief of Research · New York Cancer & Blood Specialists

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 Babylon, NY · Northeast · United StatesSpecialtyHematology / OncologyFocusOncology
Active KOLEmergingFindMyKOL type: RegionalLatest publicationSee ScholarshipOnline presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Richard Zuniga is Chief of Research at New York Cancer & Blood Specialists. OpenAlex indexes 62 publications with 888 citations (h-index 11).

Data verified 4 Nov 2026

Overview

Updated 4 Nov 2026

Richard Zuniga, MD, is Chief of Research at New York Cancer & Blood Specialists. The public record shows 62 publications with 888 citations (h-index 11), centered on Oncology. It also documents industry payments reported by 15 companies.

  • Top research focus: Oncology
  • Open Payments reporting from 15 companies

Generated from the cited public record · current as of 4 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Ovarian / Gynecologic CancerLymphomaMDS / MPNPancreatic CancerLung Cancer (NSCLC/SCLC)Gastroesophageal CancerBreast CancerMultiple MyelomaHead & Neck CancerColorectal CancerIBS / Functional GIBladder / Urothelial CancerLeukemia (AML/ALL/CML/CLL)Prostate CancerNeuro-Oncology / GliomaKidney Cancer / RCCAcromegaly

Research focus

OpenAlex concept fingerprint
Oncology

Drugs & molecules

across trials, industry payments and publications
Vonjogeneric · PacritinibClinical trials—Industry payments2Publications—Fotivdageneric · TivozanibClinical trials—Industry payments1Publications—Gazyvageneric · ObinutuzumabClinical trials—Industry payments1Publications—Krazatigeneric · AdagrasibClinical trials—Industry payments1Publications—Monoferricgeneric · Ferric derisomaltoseClinical trials—Industry payments1Publications—Ninlarogeneric · IxazomibClinical trials—Industry payments1Publications—Provengegeneric · Sipuleucel-TClinical trials—Industry payments1Publications—Wayrilzgeneric · RilzabrutinibClinical trials—Industry payments1Publications—Xospatageneric · GilteritinibClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Kite Pharma, Inc.Clinical trials—Industry payments3CTI BioPharma Corp.Clinical trials—Industry payments2Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments2Astellas Pharma US IncClinical trials—Industry payments1AVEO Pharmaceuticals, Inc.Clinical trials—Industry payments1Dendreon Pharmaceuticals LLCClinical trials—Industry payments1Genentech USA, Inc.Clinical trials—Industry payments1Genzyme CorporationClinical trials—Industry payments1Menarini Silicon Biosystems, Inc.Clinical trials—Industry payments1Mirati Therapeutics, Inc.Clinical trials—Industry payments1Myriad Genetic Laboratories, Inc.Clinical trials—Industry payments1Pharmacosmos Therapeutics Inc.Clinical trials—Industry payments1Seagen Inc.Clinical trials—Industry payments1Sirtex Medical IncClinical trials—Industry payments1Tactile Systems Technology IncClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
62publications

Publications indexed by OpenAlex. Counts exclude supporting files.

888citations

Citations across these publications.

11h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
0clinical trials

Investigator role on registered studies.

View trials ↓
15companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →

Clinical trials

We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →

Industry payments

Updated 4 Nov 2026

15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 17 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
    Article272 citations2008
    doi.org ↗
  2. 02
    Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
    Article188 citations2009
    doi.org ↗
  3. 03
    SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    Article103 citations2023
    doi.org ↗
  4. 04
    Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
    Article87 citations2010
    doi.org ↗
  5. 05
    RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer
    Article45 citations2024
    doi.org ↗
All 62 cited works: search, sort and filter.Explore →

Network

Updated 4 Nov 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Davey B. Daniel6Ian W. Flinn5Jeff Porter Sharman5David Robert Spigel5Prachi Jani5Hani M. Babiker5Roy Torcuator5Juliana M.L. Biondo5Bertrand Marquess Anz5Rajan Jain4Thomas J. Doyle4Jordi A. Rodon4Jose Caetano Villasboas4Ari M. Vanderwalde4Aung Myint Tun4Emily Stamell Ruiz4Vivek S. Chopra4Kathryn Cecilia Arbour4Pasi Antero Janne4Melissa Lynne Johnson4Jean‐François Pouliot4Kevin M. Kalinsky4Walter C. Darbonne4Guilherme Rabinowits4Lee Steven Schwartzberg4Gregory A. Vidal4Mei Wu4Yong Mun4Suraj S. Venna3Eric J. Roeland3Candace L. Haddox3Michael Robert Migden3Evan M. Braunstein3Minal A. Barve3Cynthia Dawn Timmers3Anne C. Chiang3Katja Schulze3

Background & recognition

Updated 4 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Member

    American Society of Clinical Oncology and Hematology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nycancer.com ↗
  • Member

    The European Society of Hematology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nycancer.com ↗
  • Member

    Society for Neuro-Oncology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nycancer.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.